Vanguard Group Inc. Raises Stake in Sionna Therapeutics, Inc. $SION

Vanguard Group Inc. lifted its position in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) by 3.7% in the fourth quarter, Holdings Channel reports. The firm owned 1,184,951 shares of the company’s stock after purchasing an additional 41,797 shares during the period. Vanguard Group Inc.’s holdings in Sionna Therapeutics were worth $48,749,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Goldman Sachs Group Inc. purchased a new position in Sionna Therapeutics in the 1st quarter worth approximately $667,000. Woodline Partners LP purchased a new position in Sionna Therapeutics in the 1st quarter worth approximately $837,000. Geode Capital Management LLC boosted its holdings in Sionna Therapeutics by 113.4% in the 2nd quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock worth $5,020,000 after acquiring an additional 153,712 shares during the period. Rhumbline Advisers purchased a new position in Sionna Therapeutics in the 2nd quarter worth approximately $307,000. Finally, New York State Common Retirement Fund purchased a new position in Sionna Therapeutics in the 2nd quarter worth approximately $118,000.

Sionna Therapeutics Trading Down 6.0%

Sionna Therapeutics stock opened at $40.22 on Friday. The stock has a market cap of $1.82 billion, a P/E ratio of -20.84 and a beta of 1.35. The stock has a 50 day moving average of $39.40 and a 200-day moving average of $39.54. Sionna Therapeutics, Inc. has a 52 week low of $12.42 and a 52 week high of $48.44.

Sionna Therapeutics (NASDAQ:SION) last released its earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.08). As a group, equities analysts predict that Sionna Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on SION. JonesTrading upped their price target on Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Wall Street Zen cut Sionna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Wedbush began coverage on Sionna Therapeutics in a report on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price target for the company. Guggenheim upped their price target on Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, Citigroup began coverage on Sionna Therapeutics in a report on Tuesday, February 24th. They issued an “outperform” rating for the company. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.00.

Insider Activity at Sionna Therapeutics

In related news, Director Orbimed Advisors Llc sold 184,639 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the sale, the director directly owned 2,671,822 shares of the company’s stock, valued at approximately $123,491,612.84. This represents a 6.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 184,639 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58. Following the sale, the director directly owned 2,671,822 shares in the company, valued at approximately $123,491,612.84. This represents a 6.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,717,760 shares of company stock worth $77,562,902. Corporate insiders own 3.90% of the company’s stock.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.